ArticleBJUI compass2021

Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma.

Tetsushi Murakami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.